Year Founded
2012
Ownership
Public
Therapeutic Areas
OncologyImmunology
Stage
Phase 1
Modalities
Small moleculeOtherAntibody-drug conjugate (ADC)

Nurix Therapeutics General Information

Multiple Phase 1 clinical trials ongoing for BTK degraders and CBL-B inhibitors

Contact Information

Website
Primary Industry
[ "Biotech" ]
Corporate Office
San Francisco, California
United States

Drug Pipeline

NX-2127
Phase 1
Indications: Lorem ipsum dolor sit
Modality: Lorem ipsum
Drug Asset 2
Phase X
Indications: Lorem ipsum dolor sit
Modality: Lorem ipsum
Drug Asset 3
Phase X
Indications: Lorem ipsum dolor sit
Modality: Lorem ipsum

For full access to Nurix Therapeutics's pipeline data

Book a demo

Key Partnerships

Gilead, Sanofi, Genentech

Need more data on over 80,000 life science companies, including over 1200 biotechs?

Book a demo

Nurix Therapeutics Funding

No funding data available

Early Stage VC (Series A)04-Jun-2020$38MCompletedPhase 1
Seed Round12-Feb-2019$8.5MCompletedStartup

Interested in comprehensive profile data?

We'll help you find what you need

Learn more
To view Nurix Therapeutics's complete valuation and funding history, request access »

Nurix Therapeutics Licensing Deals

AssetLicenseeDateTherapeutic Area
IRAK4 TPD programGileadMar 1, 2023
STAT6 degraderSanofiN/AImmunology
Degrader Antibody ConjugatesPfizerSep 1, 2023Oncology
STAT6 degraderSanofiDec 1, 2019Immunology
STAT6SanofiN/AImmunology
NX-1607GileadInvalid DateOncology
NX-1607SanofiInvalid DateOncology
NX-1607PfizerInvalid DateOncology
STAT6 programSanofiN/AImmunology
Undisclosed Gilead Licensed TargetGileadJun 1, 2019Oncology
Undisclosed Sanofi Licensed TargetsSanofiDec 1, 2019
Undisclosed Pfizer DAC TargetsPfizerSep 1, 2023Oncology
STAT6 degraderSanofiDec 1, 2019Immunology
You're viewing 2 of 13 licensing deals. Get the full list »

Nurix Therapeutics Investors

The Column Group
Investor Type: Venture Capital
Holding: Minority
Third Rock Ventures
Investor Type: Venture Capital
Holding: Minority
Boxer Capital
Investor Type: Venture Capital
Holding: Minority
Investor Name
Investor Type
Holding
Investor Name
Investor Type
Holding
You're viewing 3 of 5 investors. Get the full list »